Depression Research — Deep Dive

Verdicts on the contradictions · runnable analysis protocols · the prioritized hypothesis set · is the convergence model real?

Objektiv AI · Claude (Anthropic) — machine-generated from open, peer-reviewed sources.
Not medical advice.

2026-06-13

Table of Contents

1. Purpose

This deep dive pushes the two highest-value fronts further: it converts the biggest *contradictions* into current best-estimate verdicts, turns the most promising *cross-references* into executable analysis protocols, stress-tests and ranks the full hypothesis set, and asks the decisive question — is the "convergence funnel" a real unifying causal model or a convenient story? It is the actionable layer on top of the Comprehensive Synthesis and the Gaps & Frontiers report.

2. Verdicts on the core contradictions (June 2026)

Serotonin theory — superseded, not merely "debunked." The monoamine-deficit version is not viable as a primary cause. What has actually replaced it is a **neuroplasticity / TrkB model**: SSRIs, tricyclics and psychedelics all bind the BDNF receptor TrkB and promote synaptic plasticity, which may explain much of their effect independent of serotonin reuptake. Serotonin still matters in specific subtypes and via the inflammation→IDO→kynurenine route. *Verdict: stop communicating "low serotonin"; the honest model is plasticity + subtype-specific serotonergic and anti-inflammatory effects.*

Neuroinflammation — causal in a subtype, bidirectional overall. The strongest signal is drug-target Mendelian randomization for **IL-6 and TNF-α** (genetically-proxied TNF-α inhibition lowers MDD risk; higher IL-6 signalling raises depressive symptoms). **CRP**, by contrast, is null or even inverse in MR — it is a downstream marker, not a cause, and a poor instrument. *Verdict: inflammation is likely causal in a distinct ~25–40% "inflammatory subtype" (high IL-6/TNF-α), and a consequence in others; the relationship is genuinely bidirectional.*

BDNF regional contradiction — resolved as a circuit-level dissociation. Low hippocampal/PFC BDNF drives anhedonia and cognitive features; *elevated*

amygdala/nucleus-accumbens BDNF drives threat-sensitisation and stress-susceptibility. *Verdict: "BDNF is low in depression" is wrong; BDNF is a plasticity enabler whose effect depends on which circuit it strengthens.*

Antidepressant efficacy — real, modest, severity-dependent. Cipriani and Kirsch agree on the number (SMD ≈ 0.30); FDA-file analyses show ~50% publication-bias inflation. *Verdict: bias-corrected effect ≈ 0.15–0.25 — clinically meaningful mainly in severe, recurrent, or treatment-resistant depression; for mild-to-moderate first episodes the average drug–placebo gap is likely below a defensible clinical threshold, so patient preference and psychotherapy/lifestyle deserve serious weight.*

Functional unblinding — it inflates psychedelic and exercise effects. A 2026 systematic review of 112 psychedelic trials found >90% functional unblinding; the best-controlled Phase-3 psilocybin data show a real but **modest** effect (MADRS ≈ −3.6 vs placebo) — far smaller than open-label phase-2 implied. Exercise's honest effect against an expectancy-matched control is ~Hedges' g 0.3–0.5, not 0.6+. *Verdict: both effects are real but were substantially inflated; the field urgently needs agreed active-placebo standards.*

Childhood adversity — partially causal, survives the best confounding controls. Discordant-twin and sibling fixed-effects designs attenuate the association by ~30–50% but leave a meaningful causal residual (OR ≈ 1.5–2.0 for severe adversity). MR is unreliable here (adversity can't be cleanly instrumented). *Verdict: causal direction is well-supported even if the exact parameter is uncertain; mechanisms (HPA/immune epigenetic programming) are intervention targets.*

3. How the field fixes itself — a credibility checklist

The methodological frontier (MR + triangulation, target-trial emulation, negative controls, multi-ancestry GWAS, active-placebo designs, registered reports, RDoC/biotypes, digital phenotyping/EMA, consortia + replication) converges on a practical standard. **A credible causal claim in depression research should:**

1. State the causal question precisely (exposure, outcome, population, counterfactual).
2. Use ≥2 independent designs (e.g., MR + a natural experiment, or RCT + target-trial emulation).
3. Include negative-control exposures and outcomes.
4. Pre-register the outcome, analysis plan and subgroups (registry or Registered Report).
5. Report blinding integrity and adjust for expectancy in intervention studies.
6. Use heterogeneity-aware design (CRP-high/low or biotype stratification) as pre-specified.
7. Add objective/passively-sensed measures alongside self-report (actigraphy, biomarkers, EMA).
8. Power for a bias-corrected effect; apply winner's-curse shrinkage.
9. Build in replication (held-out sample or independent cohort).

10. Test measurement invariance and include ancestry/cultural diversity (flag WEIRD limits).
11. Share data and code.
12. Emulate the target trial when using observational data (TARGET reporting).

4. Four runnable-today analysis protocols

These use existing data and could be executed now.

A. PFAS × thyroid × circadian → depression (NHANES). Pool PFAS serum files (PFAS_H/I/J, P_PFAS) with thyroid (free T4 LBXFT4, TSH LBXTSH3), 2011–2014 minute-level actigraphy (derive interdaily stability, intradaily variability, relative amplitude, L5/M10 via nparACT), and PHQ-9 (DPQ). Design: **BKMR** for the PFAS mixture with thyroid and circadian metrics as parallel mediators; survey-weighted (SDMVSTRA/SDMVPSU/WTMEC). Confounders: age, sex, race, BMI, smoking (cotinine), income, iodine, medications; exclude pregnancy/thyroid meds in primary. Complete-case ≈ 1,200–1,500 (actigraphy×PFAS overlap is the binding constraint). Prior: PFNA/branched-PFOA associate with PHQ-9 depression (NHANES 2015–2018); PFAS suppress free T4.

B. PM2.5 × depression-PRS × kynurenine → depression (UK Biobank). Exposure: residential PM2.5 (fields 24006–24010). Mediator: kynurenine/tryptophan ratio from Nightingale NMR (~118k); confirm field availability or proxy IDO activity via Olink inflammation panel. PRS from the latest PGC MDD GWAS (LDpred2). Outcome: PHQ-9 (20510), ICD F32/F33 (41202). Design: PM2.5×PRS interaction, then **four-way mediation** (VanderWeele) through KTR; validate with two-step MR using IDO1/KMO cis-variants. n ≈ 80–100k with NMR. Prior: high PM2.5 + high PRS → OR ≈ 3.2 (UK Biobank GWEIS); kynurenine MR → depression OR ≈ 1.4/SD.

C. Subclinical fatty liver (MASLD) → depression via Mendelian randomization (UK Biobank/PGC). Instruments: PNPLA3 rs738409, TM6SF2 rs58542926, MTARC1, HSD17B13, GCKR (or a genome-wide liver-PDFF instrument set). Outcome: PGC MDD GWAS (+ PHQ-9 in the ~45k imaged subset for triangulation). Methods: IVW + weighted-median + MR-Egger + MR-PRESSO + CAUSE; multivariable MR conditioning on BMI and T2D to remove pleiotropy; test both directions. Note: depression→MASLD is already supported; the **liver-fat→depression** direction is the under-tested, high-value question.

D. Microplastics × gut microbiome × kynurenine → depression (feasibility). No biobank yet measures fecal/serum microplastics + microbiome + metabolomics + validated depression together. Most feasible: add **pyrolysis-GC/MS or µRaman** microplastic quantification to archived stool in an existing depression cohort with 16S/shotgun + samples (e.g., NESDA, HELIX, or the Dutch Microbiome/LifeLines), plus LC-MS/MS kynurenine/tryptophan. Design: SEM/Bayesian-network mediation (microplastics → dysbiosis → KTR → PHQ-9), WQS/BKMR by polymer type; rigorous procedural blanks (≥1 per 10) because lab contamination is the dominant validity threat; adjust for diet, antibiotics, PPIs, BMI. n ≈ 300–500 for the mediation path. This is a design blueprint / grant target, not an off-the-shelf analysis.

5. The prioritized hypothesis set

Ranked by novelty × feasibility × impact (top of the list = do first):

1. **Sleep × ultra-processed diet → IDO/kynurenine super-additivity** — testable now (PREDIMED-Plus / UK Biobank dietary subset); a 2×2 factorial would be decisive.
2. **GLP-1 receptor agonists & depression risk in a reward-deficit subtype** — urgent pharmacovigilance signal given mass prescribing; EHR study (TriNetX/Optum) stratified by baseline anhedonia/CRP.
3. **Negative social ties → accelerated epigenetic aging → depression** — strong 2026 PNAS anchoring; needs a formal mediation test (DunedinPACE on the causal path).
4. **Mitochondrial-biogenesis (PGC-1α) deficit as the shared energetic hub** of inactivity + ultra-processed diet + inflammation — explains exercise-responsive, SSRI-resistant depression.
5. **SCFA/butyrate → blood–brain-barrier → neuroinflammation axis** — actionable via fibre/probiotic trials.
6. **MASLD → depression (PNPLA3 MR)** — strong instrument, UK Biobank-ready (Protocol C).
7. **Early-adversity × prenatal-pollutant epigenetic potentiation** — high-impact developmental window; needs adequately powered interaction tests in birth cohorts.
8. **Insulin resistance as a metabolic-depression biotype** — biomarker-stratified trial (metformin/GLP-1 vs SSRI in HOMA-IR-high MDD).
9. **PFAS × thyroid × circadian** — Protocol A; NHANES holds every variable.
10. **Cadmium as the hidden smoking→depression mediator** — cheap to measure; MR feasible.
11. **PFAS × heavy-metal antagonism** — striking but counter-intuitive; validate mechanism in vitro before any interpretation.
12. **Light-at-night × metabolic dysfunction** — NHANES + satellite night-lights.
13. **HRV/vagal tone as inflammatory-vulnerability moderator** — taVNS RCT stratified by baseline HRV.
14. **IL-6 as the universal shared mediator** — lowest novelty, highest readiness for an IL-6-blockade RCT in multi-exposed, high-IL-6 patients.

6. Is the convergence funnel real? A balanced verdict

What it explains well. For roughly **25–30%** of patients — an inflammatory/metabolic subtype marked by anhedonia, fatigue and psychomotor slowing — chronic IL-6/TNF-α signalling, IDO/kynurenine activation, HPA glucocorticoid resistance and oxidative stress form mutually reinforcing loops, and anti-inflammatory augmentation shows real (if modest) benefit in CRP-stratified RCTs. HPA-axis abnormality (DST non-suppression) is among the most replicated biological findings; oxidative-stress markers (↑MDA, ↓SOD, ↓antioxidants) are consistently elevated.

Where it fails. Most depressed patients are **not** inflamed; mean cytokine elevations are small and driven by a minority. Observational evidence is heavily confounded by reverse causation (depression worsens diet/sleep/activity, which raise inflammation), and the clean MR test for CRP→depression is null or inverse. When formal mediation is done, inflammatory markers explain only ~10–30% of exposure→depression effects. Unstratified anti-inflammatory trials are largely null. Oxidative-stress evidence is associational and non-specific; cortisol lacks strong genetic instruments.

Verdict. The convergence funnel is **a well-supported partial model for a subtype, over-extended into a universal narrative.** It plausibly accounts for ~20–30% of depression aetiology — clinically important, not universal. Three studies would settle it: (1) a large, pre-registered, CRP-stratified anti-IL-6/celecoxib RCT with anhedonia/remission co-primary endpoints; (2) a multi-mediator MR using genetic instruments for IL-6, cortisol reactivity and oxidative-enzyme function simultaneously, as mediators of major exposures on MDD; (3) longitudinal single-cell/plasma multi-omics in an unselected first-episode inception cohort tracking inflammatory/HPA/oxidative trajectories through onset, remission and relapse.

7. Sources (selected)

TrkB/plasticity model of antidepressants — Trends in Neurosciences 2024 — https://doi.org/10.1016/S0166-2236(24)00154-1 · TNF-α inhibition & MDD, drug-target MR — Brain Behav Immun 2026 — https://doi.org/10.1016/j.bbi.2026.106589 · IL-6 signalling & depression MR — PMC11081733 — https://pmc.ncbi.nlm.nih.gov/articles/PMC11081733/ · CRP/IL-6 MR (HUNT) — Psychol Med 2023 — https://doi.org/10.1017/S0033291723001290 · BDNF region-specific roles — Neural Regen Res 2024 — https://doi.org/10.4103/NRR.NRR-D-23-01419 · 21-antidepressant network meta-analysis — Lancet 2018 — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32802-7/fulltext · Blinding integrity in 112 psychedelic RCTs — JAMA Psychiatry 2026 — https://doi.org/10.1001/jamapsychiatry.2026.0255 · Exercise network meta-analysis — BMJ 2024 — https://pmc.ncbi.nlm.nih.gov/articles/PMC11131084/ · Advancing an inflammatory subtype of MDD — AJP 2025 — https://pmc.ncbi.nlm.nih.gov/articles/PMC12282100/ · Anti-inflammatory treatment in elevated-inflammation depression (meta-analysis) — AJP 2025 — https://psychiatryonline.org/doi/10.1176/appi.ajp.20241115 · Kynurenine pathway in MDD — J Neuroinflammation 2026 — https://link.springer.com/article/10.1186/s12974-026-03717-2 · Oxidative-stress markers meta-analysis — PLoS ONE — https://pmc.ncbi.nlm.nih.gov/articles/PMC4596519/ · PM2.5 × gene interaction (GWEIS) — Ecotoxicol Environ Saf 2024 — https://doi.org/10.1016/j.ecoenv.2024.117121 · Kynurenine→depression MR — Sci Rep 2024 — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10799900/ · Depression→NAFLD bidirectional MR — Can J Gastroenterol Hepatol 2025 — https://doi.org/10.1155/cjgh/6632867 · PFAS & depression, NHANES — https://doi.org/10.1007/s11356-025-36917-z · Heavy metals/PFAS antagonism, NHANES

— Ecotoxicol Environ Saf 2024 — https://doi.org/10.1016/j.ecoenv.2024.116482 · Negative social ties & epigenetic aging — PNAS 2026 — https://www.pnas.org/doi/10.1073/pnas.2515331123 · GLP-1 RAs & psychiatric outcomes — Diabetes Obes Metab 2025 — https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70198 · Trans-ancestry MDD GWAS (697 loci) — Cell 2025 — https://www.cell.com/cell/fulltext/S0092-8674(24)01415-6 · TARGET reporting statement — JAMA 2024 — https://jamanetwork.com/journals/jama/fullarticle/2837724 · Microplastics alter human gut microbiome (UEG 2025) — https://www.eurekalert.org/news-releases/1100128

Compiled with AI assistance — Objektiv AI · Claude (Anthropic), 2026-06-13. Verdicts are current best estimates, not settled fact; most exposure findings are observational and causal claims rest on Mendelian randomization and trials.